



Chemical probes reveal the timing of early chlorination in vancomycin biosynthesis†

 Daniel J. Leng,^a Anja Greule,^b Max J. Cryle ^{bc} and Manuela Tosin ^{*a}

 Cite this: *Chem. Commun.*, 2021, **57**, 2293

 Received 11th November 2020,
Accepted 26th January 2021

DOI: 10.1039/d0cc07421g

rsc.li/chemcomm

Glycopeptides such as vancomycin are antibiotics of last resort whose biosynthetic pathways still hold undefined details. Chemical probes were used to capture biosynthetic intermediates generated in the nonribosomal peptide formation of vancomycin *in vivo*. The putative intercepted intermediates were characterised via HR-LC-MS². These species provided insights into the timing of the first chlorination of the peptide backbone by the halogenase VhaA: this holds significant interest for enzyme engineering towards the making of novel glycopeptides.

Nonribosomal peptides (NRPs) are a major class of secondary metabolites with a broad range of medically relevant biological activities.¹ NRPs are assembled by the multifunctional enzymes nonribosomal peptide synthetases (NRPSs), which are able to utilise proteinogenic and non-proteinogenic amino acids to give structural variety.² Each NRPS ‘module’ catalyses the addition of a single amino acid through the action of multiple domains (Scheme 1A and Fig. 1A). Specific amino acids are activated as adenosine monophosphate (AMP) esters by the NRPS adenylation domains.³ From AMP esters, amino acids are loaded onto a post-translationally modified peptidyl carrier protein (PCP) domain, as phosphopantetheine thioesters.⁴ Peptide bond formation is catalysed by the condensation (C) domain, whereby the upstream peptide is joined with a downstream aminoacyl moiety bound to a downstream PCP domain (Scheme 1A).⁵ The growing peptide intermediates can be further diversified by additional domains within the NRPS, including epimerisation, methyltransferase

and cyclisation domains.⁶ Throughout peptide chain assembly, the intermediates remain covalently bound to the NRPS as thioesters, before chain release, generally catalysed by a terminal thioesterase domain promoting peptide hydrolysis or cyclisation, occurs.⁷ Tailoring enzymes can also act on the aminoacyl growing peptide either *in trans* or post-NRPS assembly, modifying the natural product through oxidation, halogenation and glycosylation.

Vancomycin (**21**, Fig. 1) is glycopeptide antibiotic (GPA) that has been in clinical use for resistant Gram-positive bacterial infections, notably methicillin-resistant *Staphylococcus aureus* (MRSA). Vancomycin (**21**) is produced by the soil bacterium *Amycolatopsis orientalis* NRRL 2452, and it binds the D-Ala-D-Ala motif of the peptidoglycan precursor, thus inhibiting cell wall biosynthesis.⁹

The heptapeptide backbone of vancomycin is constructed by a seven module NRPS (Fig. 1A).¹⁰ It is further modified by the action of three cytochrome P450s: OxyB, OxyA and Oxy C to install the phenolic and aryl crosslinks that impart a rigid three-dimensional structure crucial for bioactivity.^{11–14} Additionally, the vancomycin β-hydroxytyrosine residues are proposed to be chlorinated by the halogenase VhaA.¹⁵ The aglycone is methylated at the N-terminal leucine, and glycosylated with the addition of glucose and vancosamine.^{16,17}

The rising resistance of *Enterococci* such as *E. faecalis* and *E. faecium* to glycopeptide antibiotics drives the urgent need for new derivatives of this vital therapeutic class. As the tailoring enzymes represent appealing tools for the preparation of novel glycopeptides, knowledge of the biosynthetic intermediates acting as substrates for tailoring enzymes is crucial.

Chemical probes of generic structure **1** have been developed in our group to enable the interrogation of nonribosomal peptide assembly lines *in vivo* (Scheme 1A).⁸ These mimic PCP-bound amino acids that act as acceptors during peptide bond formation catalysed by C domains, enabling the capture of nonhydrolysable biosynthetic intermediates for analysis by LC-MSⁿ. The presence of chlorine atoms enhances the antibiotic activity of vancomycin *in vivo*, however the timing of peptide halogenation during its biosynthesis remains


^a Department of Chemistry, University of Warwick, Gibbet Hill Road, Coventry, CV4 7AL, UK. E-mail: M.Tosin@warwick.ac.uk

^b Monash Biomedicine Discovery Institute, Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria 3800, Australia

^c ARC Centre of Excellence for Innovations in Peptide and Protein Science, Monash University, Clayton, Victoria 3800, Australia

† Electronic supplementary information (ESI) available: Contains methods for the synthesis of chemical probes and LC-HRMS analyses of the biosynthetic intermediates captured from *A. orientalis* NRRL 2452. See DOI: 10.1039/d0cc07421g





Scheme 1 (A) Nonhydrolysable chemical probes **1** mimic PCP-bound amino acids and compete with them for C-catalysed peptide bond formation, intercepting and off-loading enzyme-bound peptide species (in red) for LC-MS² analyses.⁸ (B) and (C): Synthesis of chemical probes **11–16**, **18** and **20** utilised in this study.

undetermined.^{18–20} The flavin-dependent (FADH₂) halogenase VhaA present in the cluster is thought to be responsible for both vancomycin chlorinations, as shown by production of a non-chlorinated peptide in a $\Delta bhaA$ mutant of the analogous balhimycin biosynthetic pathway.^{15,21} Most halogenases of this class act on free substrates, but examples of PCP-bound substrates have also been reported as in the pyoluteorin pathway.^{22,23} For the balhimycin producer *Amycolatopsis balhimycina* it has been previously shown that supplementation of chloro- β -hydroxytyrosine was not able to restore antibiotic production in the halogenase deficient $\Delta bhaA$ mutant, strongly suggesting that halogenation of the free amino acid does not occur.²⁴ Therefore chlorination events may occur at PCP-bound amino acid level, or on the PCP-bound peptide chain, or on the cross-linked heptapeptide aglycone. *In vitro* studies of Type IV glycopeptide teicoplanin biosynthesis has shown that the halogenase Tcp21 uses aminoacyl-PCP species as a substrate;²⁵ however, it has also been shown that VhaA *in vitro* has limited activity towards PCP-bound vancomycin hexapeptide, suggesting the chlorination of the peptide is possible.²¹ The presence of chlorinated peptides in mutant strains with inactivated Oxy enzymes suggests the halogenation of the aglycone after crosslinking is unlikely,²⁶ and Oxy activity was greater for the cyclisation of chlorinated peptides *versus* non-chlorinated ones.¹¹

A. orientalis is a largely genetically intractable strain, which has impaired efforts to obtain information on vancomycin through direct study *in vivo*. The insolubility or instability of a number of GPA biosynthetic enzymes expressed recombinantly has also posed a significant challenge.²⁷

In this work we report the use of chemical probes to investigate the timing of halogenation during vancomycin biosynthesis in its natural producer *A. orientalis* NRRL 2452. The probes utilised for this study were prepared as shown in Scheme 1B–C and detailed in the ESI.† The side chains (R₃) of their amino acid components were based on 4-hydroxyphenylglycine (Hpg) (**15**), 3,5-dihydroxyphenylglycine (Dpg) (**20**), and β -hydroxytyrosine (β HT) (**12**), which are cognate amino acids to the vancomycin NRPS, and also on non-cognate amino acids tyrosine (**11**), phenylalanine (**13**), and phenylglycine (**14**). Achiral tools based on glycine (**16**) and β -alanine (**18**) were also utilised as ‘universal’ probes, as previously reported for the investigation of echinomycin assembly.⁸ The probes were supplemented to solid and liquid cultures of *A. orientalis*, both singly and portionwise over 4 days respectively, to a final concentration of 2.0 mM. No cytotoxicity to *A. orientalis* was observed. Organic extracts of the cultures were analysed by LC-HRMS². Putative biosynthetic intermediate species intercepted by the chemical probes were identified by high-resolution mass detection and characteristic MS² fragments. These included ions resulting from peptide bond cleavages, in addition to neutral loss of water and ammonia. No obvious differences in species detected were observed between solid and liquid cultures, and a range of species ranging from dipeptides to tetrapeptides were characterised (Fig. 1 and Table 1). The ability to effectively capture intermediate species from the biosynthetic pathway varied between the probes tested, providing insights into the substrate specificity of condensation domain acceptor sites. Offloading of leucine from the first NRPS module to obtain dipeptides could be observed using non-cognate probes based upon Gly **16**, β -Ala **18**, Tyr **11** and Hpg **15** as well as the cognate β HT substrate **12**. Tripeptides were generated from intermediate offloading from the second module by Gly **16**, Tyr **11** and 4-Hpg **15**-based probes, whereas a tetrapeptide species **24** could be obtained only *via* the 4-Hpg probe **15** acting on module 4. No intercepted species were observed using Phg **13** or Phe **14**-based substrates, suggesting the phenolic groups of Tyr and 4-Hpg are important for substrate recognition by the NRPS.

The second module of the NRPS VpsA is responsible for the addition of β -hydroxytyrosine, which is halogenated during vancomycin biosynthesis. As illustrated in Fig. 1C, a chemical probe based on Hpg **15** was able to intercept both chlorinated (**23**) and non-chlorinated (**22**) peptides, with the isotopic distributions supporting the proposed intermediate structures. This suggests that halogenation occurs at the latest at the dipeptide level. This agrees with the isolation of a chlorinated dipeptide from the fermentation of engineered *A. balhimycina* bearing a truncated form of the NRPS BpsA.²⁵ Investigation of teicoplanin biosynthesis *in vitro* has also shown that hydroxylation of tyrosine is the primary factor in C-domain selectivity,






Fig. 1 (A) Postulated vancomycin nonribosomal peptide biosynthesis. (B) *In vivo* offloading and capture of early vancomycin biosynthetic intermediates by chemical probes **11–16**, **18**, and **20**, fully detailed in Table 1. Only structures related to α -amino acid based probes are shown (structures of off-loaded intermediates deriving from β -alanine probe **18** are shown in the ESI⁺). (C) Extracted ion chromatograms and HR-MS² analysis of the non-chlorinated and chlorinated peptide intermediates intercepted by the Hpg-based probe **15**, and HR-MS² analyses of these compounds containing diagnostic fragments related to probe and peptide intermediates.

accounting for the non-chlorinated peptide observed.²⁸ A chlorinated species deriving from the tripeptide offloading

Table 1 Summary of captured peptide intermediates in the biosynthesis of vancomycin (for structures please refer to Fig. 1)

Probe	R ₃	Captured species
11	CH ₂ C ₆ H ₄ OH	Di-, tripeptide
12	CH(OH)C ₆ H ₄ OH	Dipeptide
13	CH ₂ C ₆ H ₅	n.d.
14	C ₆ H ₅	n.d.
15	C ₆ H ₄ OH	Di-, tri-, tetrapeptide
16	H	Di-, tripeptide
18	—	Dipeptide
20	C ₆ H ₃ (OH) ₂	n.d.

was also identified and characterised (**24**). A probe based upon Dpg was prepared (**20**) and envisaged to intercept intermediates bound to module 6; however, this was unsuccessful and prevented the characterisation of the second chlorination event during vancomycin biosynthesis in the conditions explored here.

The identification and characterisation of a range of intercepted chlorinated peptides suggests that the donor substrate for VpsA module three is halogenated, which is important for the rational redesign of the NRPS. Species corresponding to condensation products of the C domain of module three were notably more abundant than those deriving from the condensation catalysed by module two, suggesting a broader substrate



tolerance for the third condensation domain of the vancomycin NRPS. To unequivocally support the outcomes from our *in vivo* studies, further investigations will be necessary, *e.g.* involving aminoacyl-S-PCP and dipeptidyl-S-PCP constructs operating in the presence of the halogenase VhaA *in vitro*. Quantitative mass spectrometry tools to investigate the differing ratio of intercepted species from each module would also be helpful to better rationalise C domain selectivity and kinetics throughout glycopeptide assembly *in vivo*.

Nonetheless we have here shown that chemical probes are useful tools to investigate the timing of halogenation during glycopeptide bioassembly, with focus on vancomycin and its genetically intractable producer. Future work will focus on the elucidation of the timing of the second chlorination event and of other transformation events related to glycopeptide formation.

We gratefully acknowledge BBSRC (project grant BB/J007250/1 to M. T. and MIBTP studentship to D. J. L.); the Monash Warwick Alliance (Seed Fund Award to M. T. and M. C.); Dr Cleidiane Zampronio (School of Life Sciences, Warwick) for assistance with LC-HRMSⁿ Orbitrap Fusion analyses, and Dr Lijiang Song (Warwick Chemistry) for preliminary MS data acquired on a BrukerMaXis Impact instrument.

Conflicts of interest

There are no conflicts to declare.

Notes and references

- 1 D. J. Newman and G. M. Cragg, *J. Nat. Prod.*, 2020, **83**, 770–803.
- 2 S. Caboche, M. Pupin, V. Leclère, A. Fontaine, P. Jacques and G. Kucherov, *Nucleic Acids Res.*, 2008, **36**, 326–331.
- 3 T. Stachelhaus, H. D. Mootz and M. A. Marahiel, *Chem. Biol.*, 1999, **6**, 493–505.
- 4 Ø. Frøshov, T. L. Zimmer and S. G. Laland, *FEBS Lett.*, 1970, **7**, 68–71.
- 5 V. De Crecy-Lagard, P. Marliere and W. Saurin, *C. R. Acad. Sci., Ser. III*, 1995, **318**, 927–936.
- 6 C. T. Walsh, H. Chen, T. A. Keating, B. K. Hubbard, H. C. Losey, L. Luo, C. G. Marshall, D. A. Miller and H. M. Patel, *Curr. Opin. Chem. Biol.*, 2001, **5**, 525–534.
- 7 C. A. Shaw-Reid, N. L. Kelleher, H. C. Losey, A. M. Gehring, C. Berg and C. T. Walsh, *Chem. Biol.*, 1999, **6**, 385–400.
- 8 Y. T. C. Ho, D. J. Leng, F. Ghiringhelli, I. Wilkening, D. P. Bushell, O. Kostner, E. Riva, J. Havemann, D. Passarella and M. Tosin, *Chem. Commun.*, 2017, **53**, 7088–7091.
- 9 A. N. Chatterjee and H. R. Perkins, *Biochem. Biophys. Res. Commun.*, 1966, **24**, 489–494.
- 10 J. Recktenwald, R. Shawky, O. Puk, F. Pfennig, U. Keller, W. Wohlleben and S. Pelzer, *Microbiology*, 2002, **148**, 1105–1118.
- 11 M. Peschke, C. Brieke, R. J. A. Goode, R. B. Schittenhelm and M. J. Cryle, *Biochemistry*, 2017, **56**, 1239–1247.
- 12 C. C. Forneris and M. R. Seyedshayamdoost, *Angew. Chem., Int. Ed.*, 2018, **57**, 8048–8052.
- 13 K. Woitke, N. Geib, K. Zerbe, B. L. Dong, M. Heck, S. Fournier-Roussel, O. Meyer, F. Vitali, N. Matoba, K. Abou-Hadeed and J. A. Robinson, *J. Am. Chem. Soc.*, 2007, **129**, 6887–6895.
- 14 K. Haslinger, M. Peschke, C. Brieke, E. Maximowitsch and M. J. Cryle, *Nature*, 2015, **521**, 105–109.
- 15 O. Puk, P. Huber, D. Bischoff, J. Recktenwald, G. Jung, R. D. Süßmuth, K. H. Van Pée, W. Wohlleben and S. Pelzer, *Chem. Biol.*, 2002, **9**, 225–235.
- 16 D. P. O'Brien, P. N. Kirkpatrick, S. W. O'Brien, T. Staroske, T. I. Richardson, D. A. Evans, A. Hopkinson, J. B. Spencer and D. H. Williams, *Chem. Commun.*, 2000, 103–104.
- 17 H. C. Losey, M. W. Peczu, Z. Chen, U. S. Eggert, S. D. Dong, I. Pelczar, D. Kahne and C. T. Walsh, *Biochemistry*, 2001, **40**, 4745–4755.
- 18 U. Gerhard, J. P. Mackay, R. A. Maplestone and D. H. Williams, *J. Am. Chem. Soc.*, 1993, **115**, 232–237.
- 19 J. R. Pinchman and D. L. Boger, *J. Med. Chem.*, 2013, **56**, 4116–4124.
- 20 J. R. Pinchman and D. L. Boger, *Bioorg. Med. Chem. Lett.*, 2013, **23**, 4817–4819.
- 21 P. C. Schmartz, K. Zerbe, K. Abou-Hadeed and J. A. Robinson, *Org. Biomol. Chem.*, 2014, **12**, 5574–5577.
- 22 P. C. Dorrestein, E. Yeh, S. Garneau-Tsodikova, N. L. Kelleher and C. T. Walsh, *Proc. Natl. Acad. Sci. U. S. A.*, 2005, **102**, 13843–13848.
- 23 S. Lin, S. G. Van Lanen and B. Shen, *J. Am. Chem. Soc.*, 2007, **129**, 12432–12438.
- 24 O. Puk, D. Bischoff, C. Kittel, S. Pelzer, S. Weist, E. Stegmann, R. D. Süßmuth and W. Wohlleben, *J. Bacteriol.*, 2004, **186**, 6093–6100.
- 25 T. Kittilä, C. Kittel, J. Tailhades, D. Butz, M. Schoppet, A. Büttner, R. J. A. Goode, R. B. Schittenhelm, K.-H. van Pée, R. D. Süßmuth, W. Wohlleben, M. J. Cryle and E. Stegmann, *Chem. Sci.*, 2017, **8**, 5992–6004.
- 26 R. D. Süßmuth, S. Pelzer, G. Nicholson, T. Walk, W. Wohlleben and G. Jung, *Angew. Chem., Int. Ed.*, 1999, **38**, 1976–1979.
- 27 J. W. Trauger and C. T. Walsh, *Proc. Natl. Acad. Sci. U. S. A.*, 2012, **97**, 3112–3117.
- 28 M. Kaniusaite, J. Tailhades, E. A. Marschall, R. J. A. Goode, R. B. Schittenhelm and M. J. Cryle, *Chem. Sci.*, 2019, **10**, 9466–9482.

